Latest Deals

Credit: fizkes/Shutterstock.com

Novo Holdings acquires biopharma company Paratek for $462m

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance expertise. In June 2023, Novo Holdings announced the signing of a definitive agreement to acquire Paratek. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Source: Pharmaceutical Technology

Hasten and LIB Therapeutics enter $325m CVD drug development deal

Hasten Biopharmaceutical has signed an agreement to acquire the rights for the development and commercialisation of LIB Therapeutics’ cardiovascular disease (CVD) drug lerodalcibep in Greater China.  Lerodalcibep is a PCSK9 inhibitor intended for treating patients who have greater CVD risk. It is being developed to address the limitations of existing low-density lipoprotein (LDL-C) reducing therapies for treating and preventing CVD.

Source: Pharmaceutical Technology

Pierre Fabre announces another partnership to expand oncology R&D

Medical and beauty care company Pierre Fabre Laboratories has partnered with HitGen’s UK subsidiary Vernalis to identify and develop multiple oncology drugs, in line with its shift towards cancer drug discovery. Vernalis plans to utilise fragment and structure-based methods to identify small molecules that target cancer indications and will receive milestone-based payments and a percentage of royalties from Pierre Fabre.

Source: Pharmaceutical Technology

Idorsia reacquires aprocitentan rights from Janssen for $343m

Idorsia has decided to reacquire the global rights for the oral endothelin receptor antagonist aprocitentan almost six years after they were sold to Janssen. Idorsia announced cost-reduction initiatives, including the sale of its Asia Pacific operations, in July due to “lower than anticipated” sales in H1 2023. The reacquisition of aprocitentan is expected to provide a boost to Idorsia’s profits.

Source: Pharmaceutical Technology

Go to article: Home | How pharma wants to break the efficacy ceiling in IBDGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: UrsatecGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ControlantGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article:  Sensified.ioGo to article: In DepthGo to article: How pharma wants to break the efficacy ceiling in IBDGo to article: Subcutaneous drugs grant a new lease on life to checkpoint inhibitorsGo to article: Hope for the UK clinical trial landscape but it requires a lot of work Go to article: Novo Nordisk’s Wegovy to start being supplied by NHS in EnglandGo to article: Minimal impact expected for first ten drugs released for Medicare price negotiationGo to article: Q&A: Human touch remains critical for the patient experience in trialsGo to article: Zenatek Company InsightGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue